A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxycamptothecin) in Adult Patients with Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma.

Trial Profile

A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxycamptothecin) in Adult Patients with Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2014

At a glance

  • Drugs AR 67 (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Sponsors Arno Therapeutics
  • Most Recent Events

    • 08 Dec 2014 Planned end date changed from 1 Dec 2014 to 1 Feb 2015, according to the ClinicalTrials.gov record
    • 28 Jan 2014 According to ClinicalTrials.gov. record planned end date changed from 1 Jun 2011 to 1 Dec 2014.
    • 28 Jan 2014 According to ClinicalTrials.gov. record study status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top